• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.29% Nasdaq Down0.87%

    Biodel Inc. (BIOD)

    0.42 Down 0.01(2.63%) 3:59PM EDT
    ProfileGet Profile for:
    Biodel Inc.
    100 Saw Mill Road
    Danbury, CT 06810
    United States - Map
    Phone: 203-796-5000
    Fax: 203-796-5001
    Website: http://www.biodel.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:30

    Business Summary 

    Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company is conducting a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-123, which has been evaluated in a Phase 2 clinical trial combining recombinant human insulin with its proprietary combination of excipients; and BIOD-531, a concentrated ultra-rapid-acting insulin formulation. The company was founded in 2003 and is headquartered in Danbury, Connecticut.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biodel Inc.

    Key Executives 
    Dr. Errol B. De Souza Ph.D., 62
    Chief Exec. Officer, Pres and Director
    Mr. Paul S. Bavier , 43
    Chief Admin. Officer, VP of Corp. Devel., Gen. Counsel and Sec.
    Dr. Alan Krasner M.D., 52
    Chief Medical Officer
    Mr. Gary G. Gemignani , 50
    Chief Financial Officer and Principal Accounting Officer
    Mr. Robert Feldstein , 80
    VP of Patent & Intellectual Property
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders